This ADC product is comprised of an anti-SLITRK6 monoclonal antibody conjugated via a linker to MMAE. The MMAE is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAE binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
Similar to
AGS15E
ADC Target
Name
SLITRK6
Alternative Names
SLITRK6; SLIT and NTRK-like family, member 6; DFNMYP; SLIT and NTRK-like protein 6; 4832410J21Rik; slit and trk like gene 6;
This gene encodes a member of the SLITRK protein family. Members of this family are integral membrane proteins that are characterized by two N-terminal leucine-rich repeat (LRR) domains and a C-terminal region that shares homology with trk neurotrophin receptors. This protein functions as a regulator of neurite outgrowth required for normal hearing and vision. Mutations in this gene are a cause of myopia and deafness.
ADC Antibody
Overview
Human Anti-SLITRK6 lgG2 Antibody
Species Reactivity
Human
ADC Linker
Name
protease-cleavable linker
ADC payload drug
Name
MMAE (Monomethyl auristatin E)
Description
Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.